Relevant bibliographies by topics / Pneumococcal conjugate vaccine 13

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pneumococcal conjugate vaccine 13'

Author: Grafiati
Published: 4 June 2021
Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pneumococcal conjugate vaccine 13.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pneumococcal conjugate vaccine 13"

1

Gladstone, R. A., J. M. Jefferies, S. N. Faust, and S. C. Clarke. "Continued control of pneumococcal disease in the UK – the impact of vaccination." Journal of Medical Microbiology 60, no. 1 (2011): 1–8. http://dx.doi.org/10.1099/jmm.0.020016-0.

Full text
Abstract:
Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-valent pneumococcal conjugate vaccine (PCV7) was not introduced into the UK's routine childhood immunization programme until September 2006. After its introduction, a marked decrease in the incidence of pneumococcal disease was observed, both in the vaccinated and unvaccinated UK populations. However, pneumococci are highly diverse and serotype prevalence is dynamic. Conversely, PCV7 targets only a limited number of capsular types, which appears to confer a limited lifespan to the observed beneficial effects. Shifts in serotype distribution have been detected for both non-invasive and invasive disease reported since PCV7 introduction, both in the UK and elsewhere. The pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix; GlaxoSmithKline) and 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13; Pfizer) have been newly licensed. The potential coverage of the 10- and 13-valent conjugate vaccines has also altered alongside serotype shifts. Nonetheless, the mechanism of how PCV7 has influenced serotype shift is not clear-cut as the epidemiology of serotype prevalence is complex. Other factors also influence prevalence and incidence of pneumococcal carriage and disease, such as pneumococcal diversity, levels of antibiotic use and the presence of risk groups. Continued surveillance and identification of factors influencing serotype distribution are essential to allow rational vaccine design, implementation and continued effective control of pneumococcal disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Tatochenko, V. K., and L. S. Namazova-Baranova. "13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE." Current pediatrics 11, no. 2 (2012): 44. http://dx.doi.org/10.15690/vsp.v11i2.209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ceyhan, Mehmet. "Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine." Journal of Pediatric Infection 5, no. 2 (2011): 68–73. http://dx.doi.org/10.5152/ced.2011.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ludwig, Endre, and Zsófia Mészner. "Prevention ofStreptococcus pneumoniae(pneumococcal) infections in adults." Orvosi Hetilap 155, no. 50 (2014): 1996–2004. http://dx.doi.org/10.1556/oh.2014.30070.

Full text
Abstract:
Infections caused by Streptococcus pneumoniae (pneumococcus) are still meaning a serious health problem, about 40% of community acquired pneumonia (CAP) is due to pneumococcal bacteria in adults requiring hospitalization. The incidence and mortality rate of pneumococcal infections is increasing in the population above 50 years of age. Certain congenital and acquired immunocompromised conditions make the individual susceptible for pneumococcal infection and other chronic comorbidities should be considered as a risk factor as well, such as liver and renal diseases, COPD, diabetes mellitus. Lethality of severe pneumococcal infections with bacteraemia still remains about 12% despite adequate antimicrobial therapy in the past 60 years. Underestimation of pneumococcal infections is mainly due to the low sensitivity of diagnostic tools and underuse of bacteriological laboratory confirmation methods. 13-valent pneumococcal conjugate vaccine (PCV-13) became available recently beyond the 23-valent polysacharide vaccine (PPV-23) which has been using for a long time.The indication and proper administration of the two vaccines are based on international recommendations and vaccination guideline published by National Centre for Epidemiology (NCE):Pneumococcal vaccination is recommended for: Every person above 50 years of age. Patients of all ages with chronic diseases who are susceptible for severe pneumococcal infections: respiratory (COPD), heart, renal, liver disease, diabetes, or patients under immunsuppressive treatment. Smokers regardless of age and comorbidities. Cochlear implants, cranial-injured patients. Patients with asplenia.Recommendation for administration of the two different vaccines:Adults who have not been immunized previously against pneumococcal disease must be vaccinated with a dose of 13-valent pneumococcal conjugate vaccine first. This protection could be extended with administration of 23-valent pneumococcal polysaccharide vaccine at least two month later. Adults who have been immunized previously, but above 65 years of age, with a 23-valent polysaccharide vaccine are recommended to get one dose of conjugate vaccine at least one year later. Adults who have been immunized previously, but under 65 years of age, with a 23-valent polysaccharide vaccine are recommended to get one dose of conjugate vaccine at least one year later. After a minimal interval of two months one dose of 23-valent pneumococcal polysaccharide vaccine is recommended if at least 5 years have elapsed since their previous PPSV23 dose. Vaccination of immuncompromised patients (malignancy, transplantation, etc.) and patients with asplenia should be defined by vaccinology specialists. Pneumococcal vaccines may be administered concommitantly or any interval with other vaccines. Orv. Hetil., 2014, 155(50), 1996–2004.
APA, Harvard, Vancouver, ISO, and other styles
5

Korona-Glowniak, Izabela, and Anna Malm. "Characteristics ofStreptococcus pneumoniaeStrains Colonizing Upper Respiratory Tract of Healthy Preschool Children in Poland." Scientific World Journal 2012 (2012): 1–10. http://dx.doi.org/10.1100/2012/732901.

Full text
Abstract:
Antibiotic resistant and invasive pneumococci may spread temporally and locally in day care centers (DCCs). We examined 267 children attending four DCCs located in the same city and 70 children staying at home in three seasons (autumn, winter, and spring) to determine prevalence, serotype distribution, antibiotic resistance patterns, and transmission of pneumococcal strains colonizing upper respiratory tract of healthy children without antipneumococcal vaccination. By pheno- and genotyping, we determined clonality of pneumococci, including drug-resistant strains. The average carriage of pneumococci in three seasons was 38.2%. 73.4% and 80.4% of the isolates belonged to serotypes present in 10- and 13-valent conjugate vaccine, respectively. Among the pneumococcal strains, 33.3% were susceptible to all antimicrobial tested and 39.2% had decreased susceptibility to penicillin. Multidrug resistance was common (35.7%); 97.5% of drug-resistant isolates represented serotypes included to 10- and 13-valent conjugate vaccine. According to BOX-PCR, clonality definitely was observed only in case of serotype 14. Multivariate analysis determined DCC attendance as strongly related to pneumococcal colonization in all three seasons, but important seasonal differences were demonstrated. In children attending DCCs, we observed dynamic turnover of pneumococcal strains, especially penicillin nonsusceptible and multidrug resistant, which were mostly distributed among serotypes included to available pneumococcal conjugate vaccines.
APA, Harvard, Vancouver, ISO, and other styles
6

Esposito, Susanna, and Nicola Principi. "Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children." Journal of Immunology Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/591580.

Full text
Abstract:
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.
APA, Harvard, Vancouver, ISO, and other styles
7

Morton, Ben, Kondwani Jambo, Tarsizio Chikaonda, et al. "The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol." Wellcome Open Research 6 (September 20, 2021): 240. http://dx.doi.org/10.12688/wellcomeopenres.17172.1.

Full text
Abstract:
Streptococcus pneumoniae is the leading cause of morbidity and mortality due to community acquired pneumonia, bacterial meningitis and bacteraemia worldwide. Pneumococcal conjugate vaccines protect against invasive disease, but are expensive to manufacture, limited in serotype coverage, associated with serotype replacement, and demonstrate reduced effectiveness against mucosal colonisation. For Malawi, nasopharyngeal carriage of vaccine-type pneumococci is common in vaccinated children despite national roll-out of 13-valent pneumococcal conjugate vaccine (PCV13) since 2011. Our team has safely transferred an established experimental human pneumococcal carriage method from Liverpool School of Tropical Medicine to the Malawi-Liverpool Wellcome Trust Clinical Research Programme, Malawi. This study will determine potential immunological mechanisms for the differential effects of PCV13 on nasal carriage between healthy Malawian and UK populations. We will conduct a double-blinded randomised controlled trial to vaccinate (1:1) participants with either PCV13 or control (normal saline). After a period of one month, participants will be inoculated with S. pneumoniae serotype 6B to experimentally induce nasal carriage using the EHPC method. Subsequently, participants will be invited for a second inoculation after one year to determine longer-term vaccine-induced immunological effects. Primary endpoint: detection of inoculated pneumococci by classical culture from nasal wash recovered from the participants after pneumococcal challenge. Secondary endpoints: local and systemic innate, humoral and cellular responses to PCV-13 with and without pneumococcal nasal carriage The primary objective of this controlled human infection model study is to determine if PCV-13 vaccination is protective against pneumococcal carriage in healthy adult Malawian volunteers. This study will help us to understand the observed differences in PCV-13 efficacy between populations and inform the design of future vaccines relevant to the Malawian population. Trial Registration: Pan African Clinical Trial Registry (REF: PACTR202008503507113)
APA, Harvard, Vancouver, ISO, and other styles
8

Daniels, Calvin C., P. David Rogers, and Chasity M. Shelton. "A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens." Journal of Pediatric Pharmacology and Therapeutics 21, no. 1 (2016): 27–35. http://dx.doi.org/10.5863/1551-6776-21.1.27.

Full text
Abstract:
This review describes development of currently available pneumococcal vaccines, provides summary tables of current pneumococcal vaccine recommendations in children and adults, and describes new potential vaccine antigens in the pipeline. Streptococcus pneumoniae, the bacteria responsible for pneumonia, otitis media, meningitis and bacteremia, remains a cause of morbidity and mortality in both children and adults. Introductions of unconjugated and conjugated pneumococcal polysaccharide vaccines have each reduced the rate of pneumococcal infections caused by the organism S. pneumoniae. The first vaccine developed, the 23-valent pneumococcal polysaccharide vaccine (PPSV23), protected adults and children older than 2 years of age against invasive disease caused by the 23 capsular serotypes contained in the vaccine. Because PPSV23 did not elicit a protective immune response in children younger than 2 years of age, the 7-valent pneumococcal conjugate vaccine (PCV7) containing seven of the most common serotypes from PPSV23 in pediatric invasive disease was developed for use in children younger than 2 years of age. The last vaccine to be developed, the 13-valent pneumococcal conjugate vaccine (PCV13), contains the seven serotypes in PCV7, five additional serotypes from PPSV23, and a new serotype not contained in PPSV23 or PCV7. Serotype replacement with virulent strains that are not contained in the polysaccharide vaccines has been observed after vaccine implementation and stresses the need for continued research into novel vaccine antigens. We describe eight potential protein antigens that are in the pipeline for new pneumococcal vaccines.
APA, Harvard, Vancouver, ISO, and other styles
9

Jefferies, Johanna MC, Emily Macdonald, Saul N. Faust, and Stuart C. Clarke. "13-valent pneumococcal conjugate vaccine (PCV13)." Human Vaccines 7, no. 10 (2011): 1012–18. http://dx.doi.org/10.4161/hv.7.10.16794.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kulohoma, Benard W., Katherine Gray, Arox Kamng'ona, et al. "Piliation of Invasive Streptococcus pneumoniae Isolates in the Era before Pneumococcal Conjugate Vaccine Introduction in Malawi." Clinical and Vaccine Immunology 20, no. 11 (2013): 1729–35. http://dx.doi.org/10.1128/cvi.00403-13.

Full text
Abstract:
ABSTRACTThe pneumococcal pilus has been shown to be an important determinant of adhesion and virulence in mouse models of colonization, pneumonia, and bacteremia. A pilus is capable of inducing protective immunity, supporting its inclusion in next-generation pneumococcal protein vaccine formulations. Whether this vaccine target is common among pneumococci in sub-Saharan Africa is uncertain. To define the prevalence and genetic diversity of type I and II pili among invasive pneumococci in Malawi prior to the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into routine childhood immunization, we examined 188Streptococcus pneumoniaeisolates collected between 2002 and 2008 (17% serotype 1). In this region of high disease burden, we found a low frequency of invasive piliated pneumococci (14%) and pilus gene sequence diversity similar to that seen previously in multiple global pneumococcal lineages. All common serotypes with pilus were covered by PCV13 and so we predict that pilus prevalence will be reduced in the Malawian pneumococcal population after PCV13 introduction.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pneumococcal conjugate vaccine 13"

1

Wu, Yunyan, and 吴云燕. "The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine: a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46943493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wong, Kwan-ting, and 王筠婷. "The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206978.

Full text
Abstract:
BACKGROUND: Despite the current recommendation by the Centre for Health Protection (CHP)of Hong Kong for adults aged 65 years or above to receive 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal disease(PD) has become the second leading causes of death in Hong Kong. A relatively new pneumococcal vaccine –13-valent pneumococcal conjugate vaccine (PCV13) was approved by the US Food and Drug Administration (FDA) in December 2011 and the European Medicines Agency (EMA) in July 2013 for the prevention of invasive disease caused by S. pneumoniae for older adults aged 50 years or above. It was shown to overcome some of the limitations of PPV23and potentially confer benefits to older adults in the prevention of PD. OBJECTIVES: To systematically review available literatures to examine whether PCV13 is superior to PPV23 or no vaccination in terms of the cost-effectiveness in the prevention of PD in older adults aged 50 years or above. METHODS: Two databases, PubMed and ISI Web of Science, were used to search for published journals. The year range of search in these databases was confined to10 years. RESULTS: A total of 318studies were identified initially and 10studies were included in this systematic review. Studies were conducted in the US, Colombia and European Union (EU) countries e.g. Italy, Germany, Netherlands and Spain. Different perspectives including societal, payer and health system were considered. The use of PCV13 was compared to either PPV23 or no vaccination in older adults aged 50 years or above. The coverage of PCV13 ranged from 42.4% to 70%, conferring an efficacy between 58% and 93.9%. The cost-effectiveness of PCV13 was expressed through the number of avoided cases/deaths for PD including invasive pneumococcal disease(IPD), inpatient and outpatient community-acquired pneumonia (CAP) as well as the incremental cost-effectiveness ratios (ICERs),either in cost per quality-adjusted life-year (QALY) gained or cost per life-year gained (LYG).Overall, PCV13 is shown to avoid more pneumococcal cases compared to PPV23 or no vaccination and is cost-effective in older adults aged 50 years of above. CONCLUSION: PCV13 is considered to be more cost-effective in older adults compared to PPV23 or no vaccination based on the current systematic review. Randomized controlled trials and cost-effectiveness evaluations are suggested to be conducted in Hong Kong and Asia-specific regions in order to obtain clinical and economic data of PCV13 in the Asian population. Policy-makers should also consider the effects of serotype replacement on the change in serotype distribution in local setting from time to time so that vaccines with appropriate serotype formulations could be researched.<br>published_or_final_version<br>Public Health<br>Master<br>Master of Public Health
APA, Harvard, Vancouver, ISO, and other styles
3

Arana, Jorge E. "Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers)." Digital Archive @ GSU, 2011. http://digitalarchive.gsu.edu/iph_theses/159.

Full text
Abstract:
Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS). Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a 13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months, children aged 60--71 months with underlying medical conditions, with PCV13 replacing PCV7 for all doses. Methods: We searched case reports to the Vaccine Adverse Event Reporting System (VAERS), a US passive surveillance system, for adverse events (AEs) reported after immunization with PCV13 vaccine from February 24, 2010 through February 24, 2011 for persons vaccinated from February 24, 2010 through December 31, 2010 and compared them with AEs reported by persons who were vaccinated with PCV7. Results: VAERS received 1503 reports of AEs after PCV13; multiple vaccines were given in 79.0% of reports. One hundred eighty (11.9%) were coded as serious, including nineteen reports of death. The most frequently reported symptoms were injection site reactions, fever, irritability and vomiting. Seven hundred fifty-eight (50.4%) reports comprised males. Most reports (37.7%) were from children 1-2 years. Total number of reports received for PCV13 was very similar to those received after vaccination with PCV7. Conclusions: AEs reported to VAERS following 13-valent pneumococcal conjugate vaccine were consistent with AEs previously observed in pre-licensure trials. We did not identify any major safety concerns or outcomes.
APA, Harvard, Vancouver, ISO, and other styles
4

Mezones, Holguín Edward, Aybara Carlos Canelo, Clark Andrew David, et al. "Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru." Elsevier B.V, 2015. http://hdl.handle.net/10757/582635.

Full text
Abstract:
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.<br>This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust)<br>This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA).
APA, Harvard, Vancouver, ISO, and other styles
5

Vanghelof, Joseph C. "PNEUMOCOCCAL CONJUGATE VACCINE 13 COVERAGE IN CHILDREN, HIGH-RISK ADULTS 19-64 YEARS OF AGE, AND ADULTS OVER 65 YEARS OF AGE IN A COMMERCIALLY INSURED U.S. POPULATION." UKnowledge, 2017. http://uknowledge.uky.edu/pharmacy_etds/76.

Full text
Abstract:
This thesis aimed to elucidate the demographic characteristics associated with elevated or reduced rates of pneumococcal conjugate 13 (PCV13) vaccination. A retrospective cohort study was performed using the Truven Health MarketScan® Database. Three cohorts were created corresponding to populations for which the CDC recommends PCV13 vaccination. Cohort 1: children < 36 months of age. Cohort 2: adults 19-64 years of age with high infection risk. Cohort 3: adults > 65 years of age. Odds of having a PCV13 claim were calculated for each cohort. For Cohort 1, 78% out of a total of 353,214 subjects had a sufficient number of PCV13 doses to meet CDC recommendations. For Cohort 2, 3.7% out of a total of 673,157 subjects had a PCV13 claim. For Cohort 3, 18% of 1,262,531 subjects had a PCV13 claim. Odds of vaccination were generally lower in younger subjects, those with fewer outpatient claims, and those with residence in the Northeast and South regions. In Cohort 2, odds were reduced in subjects with generalized malignancy. Gender and urban residence were poor predictors of vaccination status. By understanding the demographic factors associated with lower rates of vaccination, clinicians may more effectively direct their efforts to increase pneumococcal vaccination coverage.
APA, Harvard, Vancouver, ISO, and other styles
6

Ouldali, Naïm. "Impact à moyen terme de l'implémentation du vaccin conjugué pneumococcique 13 valences en pédiatrie : analyse de séries chronologiques interrompues." Thesis, Université de Paris (2019-....), 2020. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=4437&f=28972.

Full text
Abstract:
Introduction. Le bénéfice à moyen terme de l’implémentation des vaccins pneumococciques conjugués (VPCs) reste à préciser, du fait du remplacement sérotypique. Nous avons évalué en France, chez l’enfant, l’impact à moyen terme des VPC sur : (i) les méningites à pneumocoque, (ii) les pneumopathies aiguës communautaires (PAC), (iii) la dynamique de résistance aux antibiotiques des sérotypes pneumococciques dans le portage naso-pharyngé. Nous avons également évalué la qualité méthodologique de la littérature concernant l’impact des VPCs sur les infections pneumococciques. Méthodes. Nous avons exploité les données de 3 observatoires pédiatriques établis à l’échelle nationale : l’observatoire des méningites bactériennes de l’enfant (227 centres), l’observatoire des PAC (8 centres) et l’observatoire du portage pneumococcique (121 pédiatres de ville). Une analyse de séries chronologiques interrompues (SCI), promue par la Cochrane à la place des études avant-après, a été conduite, prenant en compte la tendance temporelle, la saisonnalité et l’autocorrélation des données, via des modèles de régression linéaire segmentée avec erreur auto-corrélée. Enfin, une revue systématique méthodologique a été conduite en incluant toutes les études évaluant l’impact des VPC sur les principales formes d’infections à pneumocoque à la fois chez l’enfant et l’adulte, via PubMed, Embase et les références des articles sélectionnés.Résultats. Après une baisse de l’incidence des méningites à pneumocoque de 38% (IC 95% [20 ; 56]) suite à l’implémentation du VPC13 en France, une remontée a été observée depuis Janvier 2015, principalement liée à l’émergence d’un sérotype non vaccinal. De la même manière, la fréquence des CAP a baissé de 44% (IC 95% [32 ; 56]) après l’implémentation du VPC13, mais depuis Juin 2014 seule une très modeste remontée a été observée. Pour le niveau de résistance des sérotypes pneumococciques, après une baisse notable suite au VPC13, une remontée progressive et constante est observée depuis Janvier 2014. Enfin, la revue systématique de la littérature a permis de sélectionner 377 études entre 2001 et 2018. Ces études utilisaient le design avant-après dans 78.5% des cas (N=296) contre 18.3% pour les SCI (N=69).Conclusion. L’impact à moyen terme des VPCs et les conséquences du remplacement sérotypique varient selon les pathologies pneumococciques. Ces résultats sont susceptibles d’évoluer dans les années à venir, nécessitant une surveillance continue. L’utilisation d’outils méthodologiques validés tels que les SCI reste minoritaire à ce jour, et doit être développée pour apprécier la complexité de l’évolution épidémiologique des infections pneumococciques au cours du temps<br>Background. Due to serotype replacement, the long-term impact of pneumococcal conjugate vaccines (PCVs) implementation remains to be evaluated. We aimed to assess, in children, the impact of PCV13 implementation on: (i) pneumococcal meningitis, (ii) community acquired pneumonia (CAP), and (iii) antibiotic susceptibility of pneumococcal strains in nasopharyngeal carriage. Finally, we conducted a methodological systematic review of the literature on assessing the impact of PCVs implementation. Methods. We used the quasi-experimental interrupted time series (ITS) analysis design with data from three French surveillance systems: (i) the national network of pediatric bacterial meningitis (230 centres), (ii) the CAP pediatric network (8 pediatric emergency departments), and (iii) an ambulatory network of pneumococcal carriage (121 pediatricians). A segmented regression model with autoregressive error was used, taking into account pre-intervention time trend, seasonality and autocorrelation. The methodological systematic review included all studies assessing the impact of PCVs implementation in children and adults, using PubMed, Embase, and references of selected articles. Results. After a 38% (95% CI [20; 56]) decrease of pneumococcal meningitis incidence following PCV13 implementation in 2010 in France, a rebound was observed since January 2015, mainly linked to the emergence of non-PCV13 serotypes. CAP rate also decreased significantly following PCV13 implementation (44% decrease, 95% CI [32; 56]), but since June 2014, only a slight increase was observed since June 2014. Regarding pneumococcal susceptibility in carriage, after a significant reduction of penicillin non-susceptibility following PCV13 implementation, a steady increase is observed since January 2014. Finally, 377 studies were included in the systematic review, from 2001 to 2018. Among them, 296 (78,5%) used the before-after design, and only 69 (18,3%) used the ITS design. Conclusions. After an important impact of PCV13, the consequences of serotype replacement in France may vary between pneumococcal disease. These findings may still evolve in the coming years, underlining the need of continuous active surveillance of these outcomes. Despite Cochrane recommendations, the use of ITS to assess PCVs impact remains largely infrequent worldwide, and needs to be promoted to adequately analyze the complex evolution of this pathogen over time
APA, Harvard, Vancouver, ISO, and other styles
7

Bahuaud, Mathilde. "Vaccination anti-pneumococcique chez les sujets à risque d'infections invasives à pneumocoques et prévention de l'hyporéponse Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): a pilot study Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study Prevention of hyporesponsiveness by modulation of schedule and doses of pneumococcal vaccine immunization." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB067.

Full text
Abstract:
Deux vaccins sont actuellement disponibles pour la prévention des infections invasives à pneumocoques (IIP) : un vaccin polysaccharidique Pneumovax® (PPV23) et un vaccin conjugué Prevenar13® (PCV13), induisant respectivement une protection contre 23 et 13 sérotypes. Le PPV23 est considéré comme faiblement immunogène, en particulier chez les personnes âgées et les patients immunodéprimés. Le PCV13, en revanche, en raison de la conjugaison à une protéine porteuse, présente l'avantage d'induire une réponse immunitaire T-dépendante, non observée avec le vaccin PPV23. Dans notre travail nous avons donc évalué l'impact des stratégies vaccinales utilisant le PCV13 et le PPV23 sur différentes populations de patients à risque. Dans une première étude, nos résultats sur la vaccination anti-pneumococcique chez des patients atteints de myélome indolent (SMM) ont montré qu'une dose de PCV13 seul, induisait une réponse immune transitoire et de faible persistance. Ces résultats suggéraient l'utilisation d'un schéma vaccinal incluant plusieurs doses de PCV13 ou une association avec le PPV23. Depuis 2013, ce schéma combiné du PCV13 et du PPV23 est le schéma recommandé par la Haute Autorité de Santé en France chez les patients à risque, avec les délais suivants : une dose de PCV13 suivie d'une dose de PPV23, 8 semaines après. Nous avons par la suite étudié cette stratégie vaccinale combinée chez des patients à risque d'IIP : patients atteints de lupus érythémateux systémique (SLE) et patients atteints de polyarthrite rhumatoïde (PR). Nos résultats montrent une immunogénicité à court terme de la stratégie combinée, mais une protection qui ne persiste pas au-delà de deux ans. De façon surprenante, les taux d'anticorps 2 ans après la vaccination, sont inférieurs aux taux pré-vaccinaux pour les patients PR. Cet effet délétère du PPV23 sur la réponse vaccinale induite par le PCV13 est appelé hyporéponse. Ce phénomène, observé chez les patients PR, ne se retrouve pas chez les patients SLE dont la vaccination PPV23 a été effectuée plus à distance du PCV13. Ces résultats suggèrent que le schéma vaccinal plus tardif (c'est-à-dire une vaccination par le PPV23 six mois après le PCV13 au lieu de deux mois) inhiberait le phénomène d'hyporéponse. Dans une troisième partie, nous avons comparé différents schéma vaccinaux modulant les doses des vaccins et les délais d'injection chez des volontaires sains mais également dans un modèle murin d'hyporéponse développé au sein du laboratoire. Notre hypothèse était que la modulation du schéma vaccinal utilisant les 2 vaccins pouvait à la fois induire une protection à long terme et prévenir l'hyporéponse. Nos résultats ont montré que l'utilisation d'une dose diminuée de PPV23 ou l'injection concomitante des deux vaccins n'empêchaient pas l'hyporéponse. En revanche, en allongeant le délai entre le PCV13 et le PPV23, le phénomène d'hyporéponse est limité. Des études cliniques chez les patients à risque d'IIP sont nécessaires afin d'évaluer une stratégie combinée tardive, où le PPV23 serait reçu au moins 6 à 12 mois après le PCV13<br>Two vaccines are currently available for the prevention of invasive pneumococcal diseases (IPD): a polysaccharide vaccine, Pneumovax® (PPV23) and a conjugate vaccine, Prevenar13® (PCV13), inducing protection against 23 and 13 serotypes, respectively. PPV23 is considered to be weakly immunogenic, particularly in the elderly and immunocompromised patients. PCV13, however, due to the conjugation to a carrier protein, has the advantage of inducing a T-dependent immune response, not observed with PPV23 vaccine. In our work, we therefore evaluated the impact of vaccine strategies using PCV13 and PPV23 on different populations of patients at risk of IPD. In a first study, our results on anti-pneumococcal vaccination in patients with smoldering myeloma (SMM) showed that a single dose of PCV13 induces a transient immune response and long term persistence. These results suggested the use of a vaccination schedule including several doses of PCV13 or association with the PPV23. Since 2013, this combined strategy of PCV13 and PPV23 is recommended by la Haute Autorité de Santé (HAS) for patients at risk, with the following delays: a dose of PCV13 followed by a dose of PPV23, 8 weeks later. We then studied this combined vaccine strategy in patients at risk of IPD: patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Our results show a short-term immunogenicity of the combined strategy, but a protection that does not persist beyond two years. Surprisingly, antibody levels 2 years after vaccination are lower than pre-vaccine levels for RA patients. This negative effect of PPV23 on PCV13-induced immune response is called hyporesponsiveness. This phenomenon, observed in RA patients, is not found in SLE patients who received PPV23 vaccination at distance from PCV13. These results suggest that the delayed vaccination schedule (ie, PPV23 vaccination six months after PCV13 instead of two months) could inhibit the hyporesponsiveness phenomenon. In a third study, we compared different vaccine strategies modulating vaccine doses and injection times in healthy volunteers but also in a mouse model of hyporesponsiveness developed in our laboratory. Our hypothesis was that modulation of the vaccine schedule using both vaccines could both induce long-term protection and prevent hyporesponsiveness. Our results showed that decreased doses of PPV23 or concomitant injection of both vaccines did not prevent hyporesponsiveness. However, by increasing the delay between PCV13 and PPV23, the phenomenon of hyporesponsiveness is limited. Clinical studies in patients at risk of IPD are needed to evaluate a delayed combined strategy, where PPV23 would be received at least 6 to 12 months after PCV13
APA, Harvard, Vancouver, ISO, and other styles
8

Mitchell, Patrick Kevin. "Pneumococcal Population Dynamics in the Conjugate Vaccine Era." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:27201746.

Full text
Abstract:
The introduction of pneumococcal conjugate vaccines (PCVs) in the early years of the 21st century have led to significant changes in pneumococcal epidemiology. Using transmission modeling and genomics based approaches, this dissertation evaluates alterations to the pneumococcal population through the PCV era. Chapter 1 presents a transmission model designed to examine factors that may influence the potential of a previously rare antibiotic resistant lineages to emerge following the introduction of a vaccine targeting more common resistant types, finding that such emergence is more likely in settings with high antibiotic use, high carriage burden, and frequent multiple carriage. Chapter 2 examines the population genomics of pediatric pneumococcal carriage before and after the introduction of PCV-13, finding that the non-vaccine type population composition experienced changes immediately following vaccine introduction but moved back towards its pre-vaccination state over time. Additionally, there is evidence that serotype 3, which is included in PCV-13, has persisted following vaccine introduction, though there are genetic differences between the pre- and post-vaccination population of this serotype. Chapter 3 compares isolates of a single non-vaccine serotype, 33F, collected from carriage and invasive disease, finding evidence that the invasive capacity of this serotype may have declined following the introduction of PCV-13 and that very closely related pairs isolates are disproportionately likely to both be from either carriage or disease. Together, these projects contribute to our understanding of how the pneumococcal population has and will continue to change as PCV use expands.
APA, Harvard, Vancouver, ISO, and other styles
9

Kwambana, Brenda Anna. "Infant nasopharyngeal microbial ecology and the pneumococcal conjugate vaccine." Thesis, University of Leicester, 2011. http://hdl.handle.net/2381/10049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Coulibaly, Aissata. "Impact of Pneumococcal Conjugate Vaccine Thirteen Valent on the Reduction of Invasive Pneumococcal Disease." ScholarWorks, 2016. https://scholarworks.waldenu.edu/dissertations/2116.

Full text
Abstract:
Many children under the age of 5 die each year of invasive pneumococcal disease. Childhood vaccination against this disease reduces morbidity and mortality. Despite the introduction of a pneumococcal conjugate vaccine (PCV13) in a central African country in 2011, all provinces have not yet been vaccinated. The purpose of this quantitative quasi-experimental study was to determine whether there was an association between the introduction of PCV13 and new cases of pneumococcal disease in 2 provinces in central Africa. The sample size for the study was 380. The theoretical framework for this study was the epidemic model supported by the concept of herd immunity. Key research questions examined the incidence of pneumococcal disease in children by age, gender, and province. The independent variables were age, gender, province, and introduction of PCV13. The dependent variable was incidence of invasive pneumococcal disease. The research questions were evaluated using chi-square test of independence and logistic regression. The results of the study indicated that vaccination with PCV13 significantly reduced incident cases of invasive pneumococcal diseases (aOR 0.333, 95% CI 0.628-0.177, p = 0.001). However, this association was not significant for age (aOR 0.574, 95% CI 1.186-0.278, p = .134), and there were no significant gender differences (aOR 1.047, 95% CI 1.929-0.569, p = 0.882). Positive social change may result by enabling the protection of more children in the central Africa country provinces that have not yet adopted using PCV13 and by introducing the vaccine in other African countries.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pneumococcal conjugate vaccine 13"

1

Nuorti, J. Pekka. Prevention of pneumococcal disease among infants and children: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP). Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

R, Siber George, Klugman Keith P, and Mäkelä P. Helena, eds. Pneumococcal vaccines: The impact of conjugate vaccine. ASM Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

T, Mayon-White Richard, and Royal Society of Medicine (Great Britain), eds. The clinical impact of pneumococcal disease and strategies for its prevention: Proceedings of an international conference sponsored by Pasteur Merieux MSD held at the Royal Society of Medicine, London, 13 December 1994. Royal Society of Medicine Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pneumococcal conjugate vaccine 13"

1

Eby, Ronald. "Pneumococcal Conjugate Vaccines." In Vaccine Design. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1823-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dagan, Ron, and Keith P. Klugman. "Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Madhi, Shabir A., and Keith P. Klugman. "Efficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Whitney, Cynthia G., and Matthew R. Moore. "Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Klugman, Keith P., Ron Dagan, Richard Malley, and Cynthia G. Whitney. "Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines." In Plotkin's Vaccines. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-35761-6.00045-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Klugman, Keith P., Steven Black, Ron Dagan, Richard Malley, and Cynthia G. Whitney. "Pneumococcal conjugate vaccine and pneumococcal common protein vaccines." In Vaccines. Elsevier, 2013. http://dx.doi.org/10.1016/b978-1-4557-0090-5.00032-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Black, Steven, Juhani Eskola, Cynthia Whitney, and Henry Shinefield. "Pneumococcal conjugate vaccine and pneumococcal common protein vaccines." In Vaccines. Elsevier, 2008. http://dx.doi.org/10.1016/b978-1-4160-3611-1.50027-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hadjivassiliou, Giorgos, and Edgar T. Overton. "“What shots do I need?”." In HIV. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190088316.003.0027.

Full text
Abstract:
This chapter reviews the current recommendations for adult persons living with HIV (PLWH) in the United States regarding vaccine-preventable diseases. In clinical practice, PLWH should be offered annual influenza vaccine; a combination of tetanus, diphtheria, and pertussis vaccine; depending on previous vaccination, pneumococcal vaccine, meningococcal conjugate vaccine, and hepatitis A and hepatitis B vaccines. Human papilloma virus vaccine can be given in PLWH up until the age of 26. Live vaccines, including the measles-mumps-rubella vaccine and varicella vaccine, can be given in those individuals who have CD4 cell counts of greater than 200 cells/mm<sup>3</sup> and did not receive these vaccines during childhood. Some expert panels endorse recombinant zoster vaccination in PLWH at least 50 years old, although there is no current official recommendation from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. The chapter covers routine vaccinations for PLWH.
APA, Harvard, Vancouver, ISO, and other styles
9

William Tong, C. Y. "Vaccine-Preventable Diseases." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0024.

Full text
Abstract:
These are diseases in which an effective preventive vaccine exists. A death that could have been prevented by vaccination is a vaccine- preventable death. The World Health Organization (WHO) has identified twenty-five diseases as vaccine preventable. This list may expand as new vaccines are being developed. The Expanded Programme on Immunization, or EPI, is vaccination programme introduced in 1974 by the WHO to all nations. The EPI initially targeted diphtheria, whooping cough, tetanus, measles, poliomyelitis, and tuberculosis. The aim was to provide universal immunization for all children by 1990 and to achieve health for all by 2000. In 2010, about 85% of children under one year of age in the world had received at least three doses of DTP vaccine (diphtheria, tetanus, and polio). Additional vaccines have now been added to the original six targets. Most countries have now added Hepatitis B (not in UK) and Haemophilus influenzae type b (Hib) to their routine infant immunization schedules, and an increasing number are in the process of adding pneumococcal conjugate vaccine and rotavirus vaccines to their schedules. Immunization is a proven tool for controlling and even eradicating infectious diseases. The immunization campaign against smallpox between 1967 and 1977 resulted in the eradication of smallpox. Apart from smallpox, the only other viral infection that was declared eradicated through vaccination campaign was rinderpest in cattle (2011), a close relative of measles virus in humans. Another major infection target for global eradication is against poliomyelitis—the global polio eradication initiative (GPEI). When the programme began in 1988, polio threatened 60% of the world’s population. Eradication of poliomyelitis is now within reach: infections have fallen by 99%; wild type polio type 2 was last detected in 1999 and declared eradicated in 2015; wild-type poliovirus type 3 has not been detected in the world since 2012. Poliovirus type 1 is the only wild- type virus in circulation and endemic transmission is only reported in Afghanistan and Pakistan. Currently, the old trivalent oral poliovirus vaccine is replaced by the more potent bivalent poliovirus type 1 and 3 vaccine. Many western countries have switched from oral vaccine to the injected inactivated vaccine to avoid the problem of vaccine- induced paralysis, which could be associated with the oral live attenuated vaccine.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pneumococcal conjugate vaccine 13"

1

Masuda, Toshihiro, Taisuke Akamatsu, Eiji Nakatani, et al. "Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hernandez Mezquita, Miguel Angel, Alexis Morales Boscam, Vanesa Hidalgo Sierra, Mercedes Sobrino Ballesteros, and Miguel Barrueco Ferrero. "Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13)." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oligbu, G., A. Djennad, S. Collins, et al. "G54 Impact of pneumococcal conjugate vaccines on pneumococcal meningitis in england and wales, 2000 – 2016." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 13–15 March 2018, SEC, Glasgow, Children First – Ethics, Morality and Advocacy in Childhood, The Journal of the Royal College of Paediatrics and Child Health. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018. http://dx.doi.org/10.1136/archdischild-2018-rcpch.52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hernandez, Miguel Angel, Alexis Morales Boscan, Vanesa Hidalgo Sierra, et al. "Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4512.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kolditz, M., J. Schmitt, M. Pletz, and F. Tesch. "Impact of the 13-valent pneumococcal conjugate vaccine on incidence of all-cause pneumonia in adults ≥ 60 years: a population-based cohort study." In 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1677993.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kolditz, M., J. Schmitt, MW Pletz, and F. Tesch. "Impact of the 13-valent pneumococcal conjugate vaccine on incidence of all-cause pneumonia in adults aged ≥60 years – a population-based retrospective cohort study." In 20. Herbsttagung der Mitteldeutschen Gesellschaft für Pneumologie und Thoraxchirurgie. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1676410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nived, P., J. Nagel, T. Saxne, et al. "FRI0162 Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis (RA) or sjogrens syndrome without dmard treatment compared to controls." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Oligbu, G., L. Pay, M. Fallaha, O. Oligbu, and U. Nwaomu. "G65(P) Risk of invasive pneumococcal disease in children with sickle cell disease in the era of pneumococcal conjugate vaccines: a systematic review of the literature." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 13–15 March 2018, SEC, Glasgow, Children First – Ethics, Morality and Advocacy in Childhood, The Journal of the Royal College of Paediatrics and Child Health. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018. http://dx.doi.org/10.1136/archdischild-2018-rcpch.63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Oligbu, G., L. Pay, M. Fallaha, O. Oligbu, and U. Nwaomu. "G370(P) Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 13–15 March 2018, SEC, Glasgow, Children First – Ethics, Morality and Advocacy in Childhood, The Journal of the Royal College of Paediatrics and Child Health. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018. http://dx.doi.org/10.1136/archdischild-2018-rcpch.360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sutter, Deena, Ashley M. Maranich, Scott Barnett, and Joshua Anchan. "Factors Affecting compliance with 13-valent Pneumococcal Conjugate Catch-up Vaccination." In Selection of Abstracts From NCE 2016. American Academy of Pediatrics, 2018. http://dx.doi.org/10.1542/peds.141.1_meetingabstract.745.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pneumococcal conjugate vaccine 13"

1

Alexandrova, Alexandra, Lena Setchanova, Daniela Pencheva, and Ivan Mitov. Molecular Serotyping of Serogroup 6 Streptococcus pneumoniae Isolates Has Shown Emergence of Serotype 6C After the Implementation of 10‑valent Pneumococcal Conjugate Vaccine (PhiD‑CV) in Bulgaria. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2019. http://dx.doi.org/10.7546/crabs.2019.08.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pneumococcal conjugate vaccine 13' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography